Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Citius Oncology highlighted positive Phase 1 data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies, presented at ASCO. The investigator-initiated study of 25 heavily pre-treated patients showed a 24% overall response rate and 48% clinical benefit rate, with a median progression-free survival of 20.5 months among responders.
Key figures
- Drug Name
- LYMPHIR (denileukin diftitox-cxdl)
- Phase Of Trial
- Phase 1
- Orr
- 24%
- M DOR
- 21.1 months (median of ongoing responses)
- M PFS overall
- 5.8 months
- Patient count
- 25
- Orr endometrial
- 33%
- Ctcl market size
- $400 million
- Evaluable patients
- 21
- Clinical benefit rate
- 48%
- M PFS clinical benefit
- 20.5 months
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.